These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 29411292)

  • 1. Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States.
    Neslusan C; Teschemaker A; Willis M; Johansen P; Vo L
    Diabetes Ther; 2018 Apr; 9(2):565-581. PubMed ID: 29411292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.
    Schubert A; Buchholt AT; El Khoury AC; Kamal A; Taieb V
    Curr Med Res Opin; 2017 Jun; 33(6):1155-1163. PubMed ID: 28323512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UK.
    Evans M; Achha S; Neslusan C
    Diabetes Ther; 2017 Oct; 8(5):1175-1185. PubMed ID: 28948541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China.
    Hou X; Wan X; Wu B
    Front Pharmacol; 2019; 10():480. PubMed ID: 31143117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective.
    Charokopou M; McEwan P; Lister S; Callan L; Bergenheim K; Tolley K; Postema R; Townsend R; Roudaut M
    BMC Health Serv Res; 2015 Nov; 15():496. PubMed ID: 26541516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Canagliflozin versus Sitagliptin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus in Mexico.
    Neslusan C; Teschemaker A; Johansen P; Willis M; Valencia-Mendoza A; Puig A
    Value Health Reg Issues; 2015 Dec; 8():8-19. PubMed ID: 29698175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Clinical Benefits of Canagliflozin 100 mg Versus Sulfonylurea in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin in India.
    Gupta V; Willis M; Johansen P; Nilsson A; Shah M; Mane A; Neslusan C
    Value Health Reg Issues; 2019 May; 18():65-73. PubMed ID: 30502662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ertugliflozin Compared to Other Anti-hyperglycemic Agents as Monotherapy and Add-on Therapy in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis.
    McNeill AM; Davies G; Kruger E; Kowal S; Reason T; Ejzykowicz F; Hannachi H; Cater N; McLeod E
    Diabetes Ther; 2019 Apr; 10(2):473-491. PubMed ID: 30689140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting.
    Stafford S; Bech PG; Fridhammar A; Miresashvili N; Nilsson A; Willis M; Liu A
    Appl Health Econ Health Policy; 2022 Jul; 20(4):543-555. PubMed ID: 35344191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Comparative Effectiveness of Canagliflozin Versus Empagliflozin and Dapagliflozin in Patients with Type 2 Diabetes in the United States.
    Blonde L; Patel C; Wu B; Chen YW; Pericone CD; Bookhart B
    Adv Ther; 2021 Jan; 38(1):594-606. PubMed ID: 33180317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of dapagliflozin versus metformin in Chinese patients whose diabetes is inadequately controlled with diet and exercise.
    Nian H; Wan X; Ma J; Jie F; Wu B
    Cost Eff Resour Alloc; 2020; 18():12. PubMed ID: 32140079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 Diabetes.
    Qiu R; Balis D; Capuano G; Xie J; Meininger G
    Diabetes Ther; 2016 Dec; 7(4):659-678. PubMed ID: 27734320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents.
    Vivian EM
    Drugs Context; 2014; 3():212264. PubMed ID: 25598831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
    Rosenthal N; Meininger G; Ways K; Polidori D; Desai M; Qiu R; Alba M; Vercruysse F; Balis D; Shaw W; Edwards R; Bull S; Di Prospero N; Sha S; Rothenberg P; Canovatchel W; Demarest K
    Ann N Y Acad Sci; 2015 Nov; 1358():28-43. PubMed ID: 26305874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous Reduction in Both HbA1c and Body Weight with Canagliflozin Versus Glimepiride in Patients with Type 2 Diabetes on Metformin.
    Leiter LA; Langslet G; Vijapurkar U; Davies MJ; Canovatchel W
    Diabetes Ther; 2016 Jun; 7(2):269-78. PubMed ID: 26984361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating Drug Cost per Response with SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus.
    Lopez JM; Macomson B; Ektare V; Patel D; Botteman M
    Am Health Drug Benefits; 2015 Sep; 8(6):309-18. PubMed ID: 26557225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of dapagliflozin as an adjunct to insulin for the treatment of type 1 diabetes mellitus in the United Kingdom.
    Bennett H; Tank A; Evans M; Bergenheim K; McEwan P
    Diabetes Obes Metab; 2020 Jul; 22(7):1047-1055. PubMed ID: 32037675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes.
    Moses RG; Colagiuri S; Pollock C
    Australas Med J; 2014; 7(10):405-15. PubMed ID: 25379062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor (SGLT-2) in treatment of type 2 diabetes mellitus.
    Molugulu N; Yee LS; Ye YT; Khee TC; Nie LZ; Yee NJ; Yee TK; Liang TC; Kesharwani P
    Diabetes Res Clin Pract; 2017 Oct; 132():157-168. PubMed ID: 28797524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
    Lavalle-González FJ; Eliaschewitz FG; Cerdas S; Chacon Mdel P; Tong C; Alba M
    Curr Med Res Opin; 2016; 32(3):427-39. PubMed ID: 26579834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.